Figure 8
ST2 deficiency impacts differentially on ES-62-mediated modulation of signalling in PDMCs and BMMCs. WT and ST2−/− PDMCs (a,b) and BMMCs (c,d) were sensitized with murine anti-DNP IgE (0.5 μg/ml) in the presence or absence of ES-62 (2 µg/ml) overnight and then incubated in medium ± IL-33 (10 ng/ml) and/or LPS (0.5 µg/ml) for 24 h at 37 °C before release of IL-6 (a,c) and IL-13 (b,d) was measured by ELISA. Data are mean ± SD values from a single experiment representative of at least two independent experiments where ***p < 0.001. Statistical analysis where three independent experiments were performed showed that whilst treatment with ES-62 resulted in 39.5 ± 19.8% p < 0.05 of the LPS- and 78.8 ± 9.0% p < 0.05 of IL33 + LPS-stimulated IL-13 production by WT PDMCs relative to the appropriate control responses, this inhibition was abolished (106 ± 10 and 106 ± 6% of the LPS and IL-33 + LPS control responses, respectively) in ST2KO PDMCs. By contrast, the LPS-induced release of IL-13 was inhibited by ES-62 in both WT and ST2−/− BMMCs (70.6 ± 6.7% WT and 63.5 ± 9.2% p < 0.05 control responses, respectively).
